論文全攻略審稿回復(fù)

1、SCI論文全攻略之審稿回復(fù)實(shí)例發(fā)布時(shí)間：2011-4-4Tags:   SCI論文   附1：SCI擴(kuò)展版和SCI核心版收錄期刊的區(qū)別  SCI擴(kuò)展版（以下簡(jiǎn)稱SCIE）和SCI核心版（以下簡(jiǎn)稱SCI）收錄期刊還是有區(qū)別的，SCI期刊論文全部被SCI收錄，SCIE期刊論文只是部分被SCI收錄，這就是有的SCIE期刊一年有幾百篇論文，卻只有幾十篇甚至十幾篇論文被SCI收錄的原因。具體到SCIE期刊上的一篇論文能否被SCI收錄，還是要看美國(guó)ISI發(fā)布的報(bào)告，現(xiàn)在科技部信息研究所也公布這一報(bào)告，很多圖書館的SCI檢索機(jī)構(gòu)也可以查。   不過

2、在國(guó)內(nèi)，很多單位都把SCI期刊論文和SCIE期刊論文一視同仁，只要發(fā)表在SCI期刊或SCIE期刊上，該論文都當(dāng)作SCI收錄，這是管理者的無能抑或無為就不得而知了。但就我們單位而言（國(guó)內(nèi)TOP10高校），這兩者還是區(qū)別對(duì)待的，論文是否SCI收錄還是看CISI的報(bào)告或SCI檢索機(jī)構(gòu)的證據(jù)。附2：如何回復(fù)SCI投稿審稿人意見(1) 1.所有問題必須逐條回答。2.盡量滿足意見中需要補(bǔ)充的實(shí)驗(yàn)。3.滿足不了的也不要回避，說明不能做的合理理由。4.審稿人推薦的文獻(xiàn)一定要引用，并討論透徹。以下是本人對(duì)審稿人意見的回復(fù)一例，僅供參考。續(xù)兩點(diǎn)經(jīng)驗(yàn)：1，最重要的是逐條回答，即使你答不了，也要老實(shí)交代；不要太狡猾，

3、以至于耽誤事；2，絕大部分實(shí)驗(yàn)是不要真追加的，除非你受到啟發(fā)，而想改投另外高檔雜志-因?yàn)槟慵热灰呀?jīng)寫成文章，從邏輯上肯定是一個(gè)完整的 “story” 了。國(guó)外雜志要求補(bǔ)充實(shí)驗(yàn)的，我均以解釋而過關(guān)。還因?yàn)椋汉苌匐s志編輯把你的修改稿再寄給當(dāng)初審稿人的，除非審稿人特別請(qǐng)求。編輯不一定懂你的東西，他只是看到你認(rèn)真修改，回答疑問了，也就接受了（當(dāng)然高檔雜志可能不是這樣，我的經(jīng)驗(yàn)只限定一般雜志（影響因子1-5）。我常用的回復(fù)格式01：Dear reviewer:I am very grateful to your comments for the manuscript. According with yo

4、ur advice, we amended the relevant part in manuscript. Some of your questions were answered below.1）2）.引用審稿人推薦的文獻(xiàn)的確是很重要的，要想辦法和自己的文章有機(jī)地結(jié)合起來。至于實(shí)驗(yàn)大部分都可以不用補(bǔ)做，關(guān)鍵是你要讓審稿人明白你的文章的重點(diǎn)是什么，這個(gè)實(shí)驗(yàn)對(duì)你要強(qiáng)調(diào)的重點(diǎn)內(nèi)容不是很必要，或者你現(xiàn)在所用的方法已經(jīng)可以達(dá)到目的就行了。最后要注意，審稿人也會(huì)犯錯(cuò)誤，不僅僅是筆誤也有專業(yè)知識(shí)上的錯(cuò)誤，因?yàn)榫庉嬚业膶徃迦宋幢厥悄氵@個(gè)領(lǐng)域的專家。只要自己是正確的就要堅(jiān)持。在回復(fù)中委婉地表達(dá)一下你的意見，

5、不過要注意商討語氣哦！我得回復(fù)格式02：Dear Professor xx:Thank you very much for your letter dated xxx xx xxxx, and the referees reports. Based on your comment and request, we have made extensive modification on the original manuscript. Here, we attached revised manuscript. in the formats of both PDF and MS word, for

6、your approval. A document answering every question from the referees was also summarized and enclosed. A revised manuscript. with the correction sections red marked was attached as the supplemental material and for easy check/editing purpose. Should you have any questions, please contact us without

7、hesitate.然后再附上Q/A，基本上囑條回答，寫的越多越好（老師語）。結(jié)果修改一次就接收了：）我的回復(fù)，請(qǐng)老外幫忙修改了。Dear Editor:Thank you for your kind letter of “.” on November *, 2005. We revised the manuscript. in accordance with the reviewers comments, and carefully proof-read the manuscript. to minimize typographical, grammatical, and bibliograp

8、hical errors.Here below is our description on revision according to the reviewers comments. Part A (Reviewer 1). The reviewers comment: .The authors Answer: .2. The reviewers comment: .The authors Answer: . Part B(Reviewer 2)1. The reviewers comment: .The authors Answer: .2. The reviewers comme

9、nt: .The authors Answer: .Many grammatical or typographical errors have been revised.All the lines and pages indicated above are in the revised manuscript.Thank you and all the reviewers for the kind advice.Sincerely yours,* 如何回復(fù)SCI投稿審稿人意見(2)  一個(gè)回復(fù)的例子(已接收)Major comments:1. The authors need

10、 to strengthen their results by including MMP secretion, and tran-matrigel migration by a positive control progenitor cell population i.e. enriched human CD34 cells obtained from mobilized PBL, since this is a more clinically relevant source of CD34 cells which has also been shown to secrete both MM

11、P-9 and MMP-2 (ref. 11). CD34 enriched cells from steady state peripheral blood which also secrete MMPs are also of interest.2. In fig1Cplease specify which cell line represents MMP-negative cells. This needs to be clarified, as well as a better explanation of the method of the protocol.3. The ELISA

12、 results are represented as "fold increase" compared to control. Instead, we suggest that standards should be used and results should be presented as absolute concentrations and only then can these results be compared to those of the zymography.4. When discussing the results, the authors s

13、hould distinguish clearly between spontaneous migration vs chemotactic migration.Furthermore, the high spontaneous migration obtained with cord blood CD34 cells should be compared to mobilized PBL CD34 enriched cells and discussed.5. The authors claim that the clonogenic assay was performed to deter

14、mine the optimum concentration for inhibition of MMP activity by phenanthroline and anti MMP-9 mAb, however they should clarify that this assay can only determine the toxicity of the inhibitors and not their optimal inhibitory concentrations.Minor comments:1. There are many spelling and syntax error

15、s, especially in the results and discussion, which need correction.a. Of special importance, is the percent inhibition of migration,which is described as percent of migration. i.e. pg 7:"Migration of CB CD34 was reduced to 73.3%?" Instead should read "Migration of CB CD34 was reduced

16、by 73.3%?"b. The degree symbol needs to be added to the numbers in Materials and methods.2. It would be preferable to combine figure1Aand B, in order to confirm the reliability of fig. 1B by a positive control (HT1080).Answer to referee 1 comment:1. Mobilized peripheral blood is a more clinical

17、 source of CD34+ cells, so it is necessary to compare the MMP-9 secretion and trans-migration ability of CB CD34+ cells with that of mobilized PB CD34+ cells. However, we couldn't obtain enough mobilized PB to separate PB CD34+ cells and determine the MMP-9 secretion and migration ability, so we

18、 couldnt complement the study on PB CD34+ cells in this paper. Results obtained by Janowska-Wieczorek et al found that mobilized CD34+ cells in peripheral blood express MMP-9. Furthermore, Domenechs study showed that MMP-9 secretion is involved in G-CSF induced HPC mobilization. Their conclusions ha

19、ve been added in the discussion. In our present study, our central conclusion from our data is that freshly isolated CD34+ stem/progenitor cells obtained from CB produce MMP-9.2. MMP-9 negative cell used in fig1Cwas Jurkat cell. In zymographic analysis, MMP-9 was not detected in the medium condition

20、ed by Jurkat cell. To exclude that the contaminating cells may play a role in the observed MMP-9 production, we screened the media conditioned by different proportion of CB mononuclear cells with MMP-9 negative cells by zymography. This result may be confusion. Actually, only by detecting the medium

21、 conditioned by 2X105 CB mononuclear cells (MNC)/ml (since the purities of CD34+ cell are more than 90%), it could exclude the MNC role. In the revised manuscript, we only detected MMP-9 activity and antigen level in the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml. There is no MMP-9 se

22、cretion be detected in the medium conditioned by 2X105 CB MNC/ml. It excluded the possibility that the MMP-9 activity in CB CD34+ cells conditioned medium is due to the contamination by MNC.3.In this revised paper, we have detected the MMP-9 antigen levels by using commercial specific ELISA kits (R&

23、amp;D System, sensitivity, 0.156ng/ml). Recombinant MMP-9 from R&D System was used as a standard. The results are expressed in the absolute concentration. The absolute concentration result has been added in the paper. As shown in Fig2, MMP-9 levels were detectable in both CB CD34+ cell condition

24、ed medium and BM CD34+ cell conditioned medium. However, MMP-9 level was significantly higher in CB CD34+ cell conditioned medium than in BM CD34+ cell conditioned medium (0.406±0.133ng/ml versus 0.195±0.023ng/ml). Although gelatinolytic activity was not detected in media conditioned by CD

25、34+ cells from BM, sensitivity of ELISA favors the detection of MMP-9 antigen in the BM CD34+.4. In our study, to establish the direct link between MMP-9 and CB CD34+ cells migration, we only determined the role of MMP-9 inspontaneous migration of CB CD34+ cells, but not in chemotactic migration. Ac

26、tually, regulation of hematopoietic stem cell migration, homing and anchorage of repopulation cells to the bone marrow involves a complex interplay between adhesion molecules, chemokines, cytokines and proteolytic enzymes. Results obtained by the groups of Voermans reveal that not only the spontaneo

27、us migration but also the SDF-1 induced migration of CB CD34+ cells is greatly increased in comparison to CD34+ cells from BM and peripheral blood.5. CD34+ cells we obtained in each cord blood sample were very limited. It is not enough to screen the inhibitors concentrations to select the optimal in

28、hibitory concentrations. In the blocking experiments, based on the concentrations used by others and the manufacturer's recommendation, we then determined the inhibitors concentrations by excluding the toxicity of the inhibitors in that concentration, which was determined by clonogenic assay.Min

29、or comments:1.The spelling and syntax errors have been checked and corrected.2.Since the results in figure1Aand B were obtained from two separated and parallel experiments, it is not fitness to combine two figures.這是我的一篇修稿回復(fù)，雜志是JBMR-A，影響因子3.652，已發(fā)表。供參考！Reply to the comments on JBMR-A-05-0172Comment:

30、Reference #10 is missing from the Introduction but used much later in the manuscript. Should these be in order used in manuscript?Reply:The missing reference has been added into the revised manuscript.Comment (continued):What is the sample size for all tests performed?Reply:The sample size for drug

31、release and PCL degradation tests was 3.0×3.0 cm2, with a thickness of about0.1mmand a weight of about 40mg. This dada have been added into the revised manuscript.Comment (continued):Figure 7. There is no scientific evidence presented in the TEM figure to convince this reviewer of sub-jets. Thi

32、s statement on Page 9 cannot be made without clear evidence during the jet formation/separation. Figure 7 is just a large fiber and small fiber fused together, no other conclusion than this can be made.Reply:Necessary change in the statements has been made in the revised manuscript. as well as in th

33、e referred figure accordingly.Comment (continued):Table 3: Need standard deviation for all values reported not just for a select few.Equation after Table 3 not necessary. Just reference method used.Reply:Done accordingly.Comment (continued):Page 11: "faster weight loss" What was the sample

34、 size? Where is the statistical analysis of this data? This reviewer does not see a significant difference in any of the data presented, thus weight loss would be considered equivalent.Reply:Although not too much difference was seen, the conclusion that “the GS/PCL membrane exhibited a relatively fa

35、ster weight loss compared with the RT/PCL membrane” was indeed applicable through “one-way analysis of variance (ANOVA)” analysis. Following the reviewers comment, a new sub-section has been added to the manuscript. to address the statistical analysis for the data.Comment (continued):Page 12: What i

36、s the sample size for release data? Looks like results based on a sample size of one? Need stand deviations on the data presented in Figure 11. Why wasn't releaseperformed and compared for all electrospun conditions investigated otherwise?Reply:Three repeated tests were performed for each set of

37、 measurements and the resulting data were averaged. As stated in the revised manuscript, each sample had a square area of 33cm2 with a slightly different thickness.Standard deviations have been added to the data shown in Fig. 11.The present manuscript. aimed to show that medical drugs ca

38、n be encapsulated in ultrafine fibers through a co-axial electrospinning process. The drug release data intended to show that the encapsulation was successful. We did not consider any specific application in this preliminary paper, and in fact the two drugs were just chosen as model illustration. As

39、 such, there seemed not necessary to perform. release experiments for all of the membranes electrospun with different conditions (i.e. the core concentrations)Comment (continued):Table 3: Yang's or Young's Modulus (page 10 says Young's).Reply:Corrected accordingly.Comment (continued):Fig

40、ure 11: What is the % release, not just concentration. Why just this small sample of release data? Where is the release data for the other conditions?Reply:Unfortunately, we did not measure the amount of the shell material in obtaining the composite nanofibers. Namely, the flow rate of the shell sol

41、ution during the electrospinning was not accurately controlled using an injecting pump. Hence the % release was not applicable. Please refer to the previous reply related to Page 12 and Figure 11 for the remaining comments.We acknowledge the reviewers comments and suggestions very much, which are va

42、luable in improving the quality of our manuscript.附3：SCI生物醫(yī)學(xué)英文論文發(fā)表成功經(jīng)驗(yàn) SCI生物醫(yī)學(xué)英文論文發(fā)表成功經(jīng)驗(yàn)共享系列一，（Clinical Chemistry）將自己近10年的科研工作中有關(guān)論文整理總結(jié)發(fā)表方面的一些信息貢獻(xiàn)出來，與大家共享！如有時(shí)間，我擬將一些已經(jīng)發(fā)表的文章，按照撰寫與發(fā)表的實(shí)際經(jīng)歷與過程，即通過案例分析每一個(gè)雜志的特色，審稿偏好，review意見及答復(fù)要點(diǎn)等逐一分析。可能包含的雜志系列有：nature methods，clinical chemistry，analytical chemistry，J. Cl

43、in. Immuno，Biomed. Microdev，F(xiàn)ront. Biosci，Mol. Cell. Biochem，J. Expert，Rev. Proteomics，J biochemistry等。本章先講解美國(guó)Clinical Chemistry雜志，一個(gè)臨床化學(xué)界的王牌雜志，近年其影響因子逐年攀升，現(xiàn)為7.7分。Clinical Chemistry由美國(guó)AACC每月出版，接受的文章包括與人體疾病相關(guān)的實(shí)驗(yàn)室研究，分析與分子診斷，儀器，資料處理，數(shù)據(jù)分析，臨床研究等投稿。ISSN：0009-9147網(wǎng)絡(luò)版ISSN：1530-8561【URL】http:/intl.clinchem.o

44、rg/【鏡像URL】/【出版者】American Association for Clinical Chemistry (AACC)【收費(fèi)情況】 免費(fèi)，全文【內(nèi)容簡(jiǎn)介】Clinical Chemistry is an international journal of laboratory medicine and molecular diagnostics.Clinical Chemistry - This highly respected and often-cited scientific journal is published monthly

45、 and contains peer-reviewed methodology, research papers and other articles relevant to clinical chemistry and related laboratory sciences. Its circulation is more than 15,000.David E. Bruns, MD, Editor, (Charlottesville Office)Sandra Weaver, Senior Editorial Assistantsweaverc

46、Donna Brandl, Editorial AShane P. Cyr, Editorial AMac Fancher, Publisher, (WashingtonOffice)Miriam Gonzalez, Publications C【目錄、摘要或全文上網(wǎng)等情況】Free TOC, 1965 -Free Abstract, 1975 -Free

47、Fulltext, 1997 -1999Fulltext, 1997 - 【雜志被索引的情況】Indexed in Chemical Abstracts.【備注】For faster access to Clinical Chemistry Online from these countries use this URL:Australia, Brazil, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Mexico,Russia, Singapore,

48、 South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, The Netherlands, UK該雜志是由美國(guó)臨床化學(xué)協(xié)會(huì)（American Association for Clinical Chemistry，AACC）主辦的，于1948年成立，總部位于華盛頓，擁有1萬余會(huì)員。先在網(wǎng)站注冊(cè)，登記，按照提示一步步提供文章名稱，摘要，作者姓名，所屬領(lǐng)域，關(guān)鍵詞，主文，圖表等等。轉(zhuǎn)換為PDF后就可以提交，然后給你一個(gè)查詢號(hào)，接著就是等待了。等了20多天，查閱狀態(tài)看到了第一次回信：Home Author Area Reviewer

49、 Area Personal Info. ClinChem Home Sign Out Submit New Manuscript. Information for Authors Queue Summary Feedback Help FAQDecision LetterReturn to QueueTo:作者姓名（電子郵件）From: Subject: Clinical Chemistry - Manuscript. DecisionCc:RE: Clinical Chemistry MS ID# CLINCHEM/2002/03633

50、2TITLE:Dear Dr. xxx:Your manuscript. has been examined by two expert reviewers. Please visit to view their comments. For the reasons detailed in these comments, we cannot accept this manuscript. for publication in Clinical Chemistry in this form. Also, your Reference 28 is

51、not formatted properly. Our Information for Authors will offer assistance with journal style; it can be found at/ccj/infoauth.stmWe would consider a revised version that takes these criticisms into account. If you should resubmit the paper I would also ask that you have several Eng

52、lish speaking colleagues proof the paper for grammar and composition. Additionally, be sure to provide a detailed point-by-point response to the comments of the reviewers. Failure to do so will delay consideration of the revised manuscript.Prior to publication we require copyright releases signed by

53、 all authors. Our Authors Assurances and Assignment of Copyright form. can be downloaded from /ccj/auth_assure02.pdf. Please note that all authors must sign both sections of the form. (a signature on the lower section means that all conflicts of interest have been disclosed even if

54、 there are none). Send the completed form. to us by FAX (434-979-7599).Sincerely,Dr. xxx nesleyAssociate EditorP.S. You will find your revised manuscript. can be uploaded in your "Submit a Revision" queue at . Please do not begin the submission of your revised manu

55、script. until you are ready to submit the entire manuscript. A checklist regarding requirements for submission can be found at/ccj/manuscript_check02.pdf. Figures must be uploaded as Image Files in .tif or .eps files at 600 DPI. Alternatively, you may use PowerPoint software for fi

56、gures but fonts must be embedded and only one image per slide, one slide per file. When uploading the revised version, please be sure to include in the "Response to Reviews" field a point-by-point list of all changes made, or your rebuttal, in response to each of the reviewers?suggestions.

57、P.P.S. Please note that if your manuscript. has color figures, the authors are expected to bear the cost of printing them, except in the case of invited papers. The charges for these figures are $1500 for the first color figure or part of a figure, and $500 for each additional color figure or part o

58、f a figure. Authors will be billed for color publication costs unless they request that their figures be printed in black and white.該雜志一般為2個(gè)審稿人，審稿過程也較嚴(yán)格，都是本領(lǐng)域的大牛。后來我還有幸在一次會(huì)議上認(rèn)識(shí)到一個(gè)當(dāng)年的審稿人，但不知道是1還是2，呵呵！一般總是先鼓勵(lì)一段話，不寫了。下面問題就來了，共12個(gè)，有些很好回答，一句話就可以解釋清楚，有些就比較麻煩。還是舉例說明把-1）實(shí)驗(yàn)的有效性和深度（at least for a few substances of major importancedetection limits, cut-off values and specificity should have beenstudied. Also the description of the assay principle is not quiteclear）沒辦法，只有一條路，補(bǔ)充相關(guān)實(shí)驗(yàn)，然后再投。2）語言問題（The English text would have to be substantially improved）雖然這是一個(gè)美國(guó)雜志，但對(duì)語言的要求一點(diǎn)都不弱，投之前還是忽略了，沒辦法，慢慢修